Cogent Biosciences COGT Cash Flow Statement (2017-2026)

NASDAQ COGT
$34.78 -0.17 (-0.49%)
As of: Sep 4, 2026 · 2:26 PM EDT
Reported Financials

Cogent Biosciences Quarterly Cash Flow Statement

Periods 38 quarters
Latest Jun 2026

Cogent Biosciences reported cash from operations of -$77.27M and free cash flow of -$77.64M for the quarter ended Jun 2026, down 41.7% year over year. This cash flow statement covers 38 quarters of results from Mar 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-19.70M-25.53M-31.31M-35.58M-35.32M-41.63M-40.97M-44.34M-55.38M-54.36M-58.35M-58.99M-70.64M-69.88M-71.98M-73.52M-80.93M-95.31M-97.21M-96.39M
Share-based Compensation
3.72M3.85M4.17M4.53M4.62M5.85M7.16M8.76M8.85M9.39M10.01M10.36M9.98M10.01M9.72M10.60M1.10M16.91M17.11M
Deferred Taxes
Cash from Operations
-14.11M-20.78M-28.33M-26.46M-34.44M-29.41M-39.52M-32.07M-37.97M-44.07M-52.53M-42.70M-51.98M-60.58M-66.51M-54.54M-64.29M-79.11M-86.88M-77.27M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.47M0.48M0.49M0.57M3.46M0.52M1.04M0.74M-0.66M4.05M1.40M-2.58M6.20M2.60M0.95M0.04M0.51M0.51M1.18M0.96M
Amortization of Deferred Charges
0.06M0.30M0.24M0.28M0.28M
Depreciation & Amortization (CF)Depreciation & Amortization
0.05M0.07M0.07M0.10M0.26M0.38M0.53M0.56M0.58M0.63M0.60M0.61M0.62M0.68M0.64M0.66M0.64M0.66M0.63M0.74M
Change in Working Capital
Change in Receivables
Change in Account Payables
2.36M-0.87M0.53M-0.52M0.60M1.75M-1.67M2.99M2.71M0.79M4.91M-6.59M6.09M-3.05M2.14M2.47M-0.60M-6.53M4.24M-6.26M
Change in Accured Expenses
0.60M1.16M0.20M2.97M2.61M3.81M-2.56M1.85M6.25M2.63M-6.72M10.10M6.92M5.66M-8.66M5.68M4.57M9.10M-10.20M7.62M
Other Working Capital Changes
1.37M-1.67M0.74M0.17M2.21M-1.63M0.32M0.37M1.79M-1.85M1.10M0.59M-0.75M3.39M-2.17M-0.06M-0.81M3.24M1.83M-0.30M
Investing Activities
Capital Expenditures
1.16M0.43M0.44M1.14M3.31M1.97M1.10M1.26M0.12M0.32M0.07M0.15M0.28M0.07M0.55M0.13M0.07M0.81M0.45M0.37M
Change in Acquisitions & Divestments
120.00M50.00M22.06M61.72M74.13M65.92M79.93M74.47M69.93M76.92M69.08M73.26M97.83M97.46M
Cash from Investing Activities
-1.16M-0.43M-0.44M-1.14M-151.54M28.41M59.88M-77.66M-90.54M10.49M1.04M-84.62M60.19M61.67M69.38M8.91M-155.05M-322.77M-36.46M14.28M
Financing Activities
Other financing activities
0.13M0.79M0.32M0.31M0.65M0.36M0.56M-0.00M0.58M215.21M-204.25M5.76M2.96M
Debt Issuance and Repayment
Long-Term Debt Issuances
5.34M
Change in Capital Stock
Net Shares Issued and Repurchased
3.40M4.72M3.30M6.19M7.54M
Net Equity Issued and Repurchased
161.80M24.30M135.00M
Misc.
Cash from Financing Activities
0.06M38.01M0.14M162.12M0.99M0.32M0.45M162.09M1.00M214.06M-0.26M0.62M0.03M24.97M47.23M217.37M588.67M52.54M2.96M
Exchange Rate Effect
-0.28M
Change in Cash
-15.22M16.80M-28.64M134.51M-184.99M-0.68M20.81M52.36M-127.51M-33.58M162.57M-127.58M8.83M1.12M27.84M1.59M-1.97M186.79M-70.80M-60.04M
Free Cash Flow
-15.27M-21.21M-28.77M-27.60M-37.75M-31.38M-40.62M-33.32M-38.09M-44.38M-52.60M-42.85M-52.26M-60.65M-67.06M-54.67M-64.35M-79.92M-87.33M-77.64M
Net Cash Flow
-15.22M16.80M-28.64M134.51M-184.99M-0.68M20.81M52.36M-127.51M-33.58M162.57M-127.58M8.83M1.12M27.84M1.59M-1.97M186.79M-70.80M-60.04M